Contribute Try STAT+ Today

Medical datasets marketed by data aggregators contain detailed information about the health conditions of millions of Americans. With the help of artificial intelligence, they could also be a boon in efforts by both providers and drug makers to identify people who don’t yet realize they have a serious disease.

In a study published Monday, a machine learning model scoured aggregated medical data on 170 million Americans and flagged 1.3 million of them as likely to have an inherited condition known as familial hypercholesterolemia, which causes high cholesterol and elevates risk for heart attacks and strokes. It’s not clear how many of the people who were identified actually have FH. But the project has spurred a first-of-its-kind effort to partner with health systems to notify patients identified by the AI system, and, when appropriate, get them diagnosed and treated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy